UPMC Heart and Vascular Institute in central Pennsylvania has treated its first patient with a new therapy.

The data thus far suggest fewer repeat interventions with the newly FDA approved resorbable device compared with PTA.

The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the first two rounds ...

Their dominance is underscored by continuous advancements in stent design, materials, and coatings, aimed at enhancing ...

Investigators from the LIFE-BTK randomized controlled trial evaluating the use of the Drug-Eluting Resorbable Scaffold (Abbott) ...

UPMC Heart and Vascular Institute in Central Pa. has treated its first patient with a new therapy for in-stent restenosis (ISR), a condition in which scar tissue forms inside the ...

WASHINGTON, DC—For patients with simple, true coronary bifurcations treated with a provisional-stenting strategy, use of a ...

The company is preparing to launch an early feasibility study in the US to further evaluate the treatment for coronary lesions.

The RESTO (Morphological Parameters of In‐Stent Restenosis Assessed and Identified by OCT [Optical Coherence Tomography]; study NCT04268875) was a prospective multicenter registry including patients ...

One side of the trial will randomize patients needing in-stent restenosis head-to-head against Boston Scientific’s Agent balloon. Meanwhile, a single-arm portion will focus on Prevail in de novo ...

Percutaneous coronary intervention (PCI) is currently the main method for treating coronary artery stenosis, but the incidence of restenosis after PCI is relatively high. Restenosis, the narrowing of ...